Verastem Oncology (VSTM) was founded in 2010 and is based in the Boston area (Needham).
The company has an FDA-approved product, Copiktra. The stock was beaten down since the drug got approved. Management announced a change in its strategy and decided to shift its focus to the newly acquired molecule CH5126766, an RAF/MEK inhibitor that was licensed from Chugai. The molecule has shown signs of activity in early clinical studies as monotherapy in KRAS mutation-positive solid tumors like non-small cell lung cancer (NSCLC), endometrial cancer, ovarian cancers, and BRAF+ ovarian cancer. It is